A Brief History of Cue Biopharma, Inc. (CUE)

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel and proprietary class of biologics to selectively modulate disease-relevant T cell subsets to improve clinical outcomes for patients. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.

• 2015: Cue Biopharma was founded with the vision of harnessing the body's immune system to treat a variety of diseases, including cancer and autoimmune disorders.
• 2016: The company announced a strategic collaboration with Merck, a leading pharmaceutical company, to develop innovative biologics for the treatment of cancer.
• 2017: Cue Biopharma completed a successful initial public offering (IPO) on the NASDAQ stock exchange, raising funds to further advance its pipeline of novel biologics.
• 2018: The company initiated several clinical trials to evaluate the safety and efficacy of its lead drug candidates in patients with various types of cancer.
• 2019: Cue Biopharma announced positive results from early-stage clinical trials, demonstrating the potential of its biologics to selectively target disease-relevant T cell subsets.
• 2020: Despite the challenges posed by the COVID-19 pandemic, Cue Biopharma continued to make progress in advancing its pipeline of novel biologics and exploring new therapeutic opportunities.

Who Owns Cue Biopharma, Inc. (CUE)

Cue Biopharma, Inc. (CUE) is a clinical-stage biopharmaceutical company focused on developing a novel class of biologic drugs designed to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.

As of the latest available data, the ownership structure of Cue Biopharma, Inc. is as follows:

• Institutional Investors: Institutional investors own a significant portion of Cue Biopharma, Inc. These investors include venture capital firms, mutual funds, and other institutional entities that have invested in the company.
• Insiders: Insiders such as company executives, directors, and employees also hold ownership stakes in Cue Biopharma, Inc. These individuals may have acquired shares through stock options, grants, or direct purchases.
• Retail Investors: Retail investors, including individual shareholders who trade on the open market, also own a portion of Cue Biopharma, Inc. These investors may have purchased shares through a brokerage account or other investment platforms.

Overall, Cue Biopharma, Inc. has a diverse shareholder base that includes institutional investors, insiders, and retail investors who have a stake in the company's success and future growth.

Cue Biopharma, Inc. (CUE) Mission Statement

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of immunomodulatory biologics to selectively engage and modulate a patient's own immune system to treat a broad range of cancers and autoimmune diseases.

The company's mission is to provide innovative treatment options for patients with challenging diseases by leveraging its proprietary platform technology to develop highly selective biologics that target and modulate specific disease-associated T cells in the body.

• Developing novel immunotherapies
• Advancing precision medicine
• Improving patient outcomes
• Enhancing quality of life

How Cue Biopharma, Inc. (CUE) Works

Cue Biopharma, Inc. is a biopharmaceutical company that is focused on developing a novel class of immunotherapies designed to selectively modulate disease-relevant T cell subsets to treat a range of cancers and autoimmune diseases. The company's technology platform is based on the Cue Biologics program, which is designed to harness the body's immune system to attack disease-causing cells while leaving healthy cells unharmed.

One of the key aspects of Cue Biopharma's technology is the Immuno-STAT platform, which enables the company to design and develop biological drugs that target and modulate disease-relevant T cells. These drugs are engineered to specifically bind to T cells and deliver a signal that activates or suppresses the cells' activity, depending on the desired therapeutic effect.

By targeting specific subsets of T cells, Cue Biopharma's therapies have the potential to provide more precise and effective treatments for cancer and autoimmune diseases, with fewer side effects compared to traditional therapies that impact the entire immune system.

The company is currently advancing several programs through preclinical and clinical development, with the goal of bringing new treatment options to patients in need. Cue Biopharma collaborates with leading academic institutions, research organizations, and biopharmaceutical companies to further develop and validate its technology platform.

• Immunotherapy: Cue Biopharma focuses on developing immunotherapies that selectively modulate disease-relevant T cell subsets.
• Immuno-STAT platform: The company's technology platform enables the design and development of biological drugs that target and modulate T cell activity.
• Precision medicine: By targeting specific T cell subsets, Cue Biopharma aims to provide more precise and effective treatments with fewer side effects.

How Cue Biopharma, Inc. (CUE) Makes Money

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company that focuses on developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune diseases. The company generates revenue through various channels:

• Collaborations: Cue Biopharma partners with other biopharmaceutical companies to develop and commercialize therapeutic products. These collaborations often involve upfront payments, milestone payments, and royalties on sales of any successfully developed drugs.
• Licensing Agreements: The company may enter into licensing agreements with other companies to grant them the rights to use Cue Biopharma's technology or intellectual property. These agreements can provide Cue Biopharma with upfront payments, milestone payments, and royalties on any products developed using their technology.
• Research and Development Grants: Cue Biopharma may receive funding from governmental agencies, non-profit organizations, or private foundations to support its research and development efforts. These grants can help offset R&D expenses and provide additional revenue streams for the company.
• Sales of Intellectual Property: Cue Biopharma may generate revenue by selling or licensing its intellectual property rights, such as patents or proprietary technology, to other companies in the biopharmaceutical industry.
• Investments and Partnerships: The company may also generate revenue through strategic investments in other biopharmaceutical companies or through partnerships that involve equity stakes in other businesses.